Department of Molecular Genetics, Ahar Branch, Islamic Azad University, Ahar, Iran.
Eye Research Center, The Five Senses Health Institute, Rassoul Akram Hospital, Iran University of Medical Sciences, Tehran, Iran.
BMC Res Notes. 2023 May 8;16(1):72. doi: 10.1186/s13104-023-06343-w.
Breast cancer (BC) is one of the most common cancers with a high mortality rate in women worldwide. The advantages of early cancer diagnosis are apparent, and it is a critical factor in increasing the patient's life and survival. According to mounting evidence, microRNAs (miRNAs) may be crucial regulators of critical biological processes. miRNA dysregulation has been linked to the beginning and progression of various human malignancies, including BC, and can operate as tumor suppressors or oncomiRs. This study aimed to identify novel miRNA biomarkers in BC tissues and non-tumor adjacent tissues of patients with BC. Microarray datasets GSE15852 and GSE42568 for differentially expressed genes (DEGs) and GSE45666, GSE57897, and GSE40525 for differentially expressed miRNAs (DEMs) retrieved from the Gene Expression Omnibus (GEO) database were analyzed using "R" software. A protein-protein interaction (PPI) network was created to identify the hub genes. MirNet, miRTarBase, and MirPathDB databases were used to predict DEMs targeted genes. Functional enrichment analysis was used to demonstrate the topmost classifications of molecular pathways. The prognostic capability of selected DEMs was evaluated through a Kaplan-Meier plot. Moreover, the specificity and sensitivity of detected miRNAs to discriminate BC from adjacent controls were assessed by area under the curve (AUC) using the ROC curve analysis. In the last phase of this study, gene expression on 100 BC tissues and 100 healthy adjacent tissues were analyzed and calculated by using the Real-Time PCR method.
This study declared that miR-583 and miR-877-5p were downregulated in tumor samples in comparison to adjacent non-tumor samples (|logFC|< 0 and P ≤ 0.05). Accordingly, ROC curve analysis demonstrated the biomarker potential of miR-877-5p (AUC = 0.63) and miR-583 (AUC = 0.69). Our results showed that has-miR-583 and has-miR-877-5p could be potential biomarkers in BC.
乳腺癌(BC)是全球女性中发病率和死亡率较高的最常见癌症之一。早期癌症诊断的优势显而易见,这是提高患者生存率和生存质量的关键因素。越来越多的证据表明,微小 RNA(miRNA)可能是关键生物过程的重要调节剂。miRNA 失调与多种人类恶性肿瘤的发生和发展有关,可作为肿瘤抑制因子或癌基因。本研究旨在鉴定乳腺癌组织和乳腺癌患者非肿瘤相邻组织中的新型 miRNA 生物标志物。从基因表达综合数据库(GEO)中分析了基因表达谱数据集 GSE15852 和 GSE42568 中差异表达基因(DEGs)以及 GSE45666、GSE57897 和 GSE40525 中差异表达 miRNA(DEM),使用“R”软件进行分析。创建蛋白质-蛋白质相互作用(PPI)网络以识别枢纽基因。使用 MirNet、miRTarBase 和 MirPathDB 数据库预测 DEM 靶向基因。功能富集分析用于展示分子途径的最重要分类。通过 Kaplan-Meier 图评估选定 DEM 的预后能力。此外,通过 ROC 曲线分析 AUC 评估检测 miRNA 区分 BC 与相邻对照的特异性和敏感性。在本研究的最后阶段,使用实时 PCR 方法分析并计算了 100 例乳腺癌组织和 100 例健康相邻组织的基因表达。
本研究表明,与相邻非肿瘤样本相比,肿瘤样本中 miR-583 和 miR-877-5p 表达下调(|logFC|<0 和 P≤0.05)。因此,ROC 曲线分析表明 miR-877-5p(AUC=0.63)和 miR-583(AUC=0.69)具有作为生物标志物的潜力。我们的结果表明,has-miR-583 和 has-miR-877-5p 可能是 BC 的潜在生物标志物。